Skip to content
Open in App
Samsung Biologics logo

Samsung Biologics

web2

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commer...

Symbol · 207940
Company profile

About

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance. In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

First US manufacturing site joins Samsung Biologics network

KEY STEP

Samsung Biologics established its first US manufacturing presence through the Rockville, Maryland facility, adding 60,000 liters of drug substance capacity and bringing total global manufacturing capacity to 845,000 liters.

Roadmap reference

PolyPeptide public tender offer period opens

KEY STEP

Samsung Biologics announced that the main public tender offer period for PolyPeptide Group shares is scheduled to commence on September 15, 2026, subject to the terms and conditions in the offer prospectus.

Roadmap reference

Rights offering shares targeted for listing

KEY STEP

Samsung Biologics announced that new shares from its KRW 3 trillion rights offering are targeted for listing on November 30, 2026. The proceeds are intended mainly to finance the PolyPeptide acquisition and additional Bio Campus II investment.

Roadmap reference
People

Company team

JC

John Chongbo Rim

CEO, President & Chairman of Board

Company leadership profile.

Sh

Seung ho Ryu

EVP, CFO, Head of Business Support Center & Director

Company leadership profile.

KL

Kun Lo

Executive VP, Head of EPCV Center & Director

Company leadership profile.

CL

Changwoo Lee

Independent Director

Company leadership profile.

SH

Seoung Hwan Suh

Independent Director

Company leadership profile.

HS

Ho Seung Lee

Independent Director

Company leadership profile.

JK

Jungyeun Kim

Independent Director

Company leadership profile.

Expert coverage

1 expert evaluated Samsung Biologics.

Orbitrum research

Experts evaluating Samsung Biologics

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment